Home / Business and Economy / Biotech Stocks: 5 Long-Term Investment Buys
Biotech Stocks: 5 Long-Term Investment Buys
9 Nov
Summary
- Vertex Pharmaceuticals leads in cystic fibrosis and pursues kidney disease treatments.
- Amgen shows robust growth with 17 products achieving double-digit year-over-year sales.
- Gilead Sciences expands beyond HIV into a promising oncology pipeline.
- Exelixis carves a niche in oncology with its key drug Cabometyx.
- Regeneron Pharmaceuticals rebounds with new Eylea formulations and Dupixent.
As of November 2026, the biotechnology sector, while historically volatile, showcases several companies with strong long-term investment potential. Vertex Pharmaceuticals continues its dominance in cystic fibrosis treatment and is advancing promising kidney disease therapies like povetacicept and inaxaplin. Amgen stands out as a diversified giant, boasting 17 products with double-digit sales growth and 17 medicines achieving over $1 billion in annual revenue, supported by a deep pipeline including the weight-loss drug MariTide.
Gilead Sciences, traditionally known for its leading HIV drugs, is strategically expanding its pipeline with a significant focus on oncology. Exelixis has successfully carved out a niche within the competitive oncology market with its multi-indication drug Cabometyx, and is poised for future growth with new investigational therapies. Regeneron Pharmaceuticals is experiencing a rebound, driven by new formulations of Eylea and Dupixent, and is exploring innovative treatments, including weight-loss candidates.
